Concord Biotech Limited

Pharmaceuticals

Annual Returns

Cumulative Returns and Drawdowns



Fundamentals














Ownership




Margined





AI Summary

asof: 2026-09-16

Concord Biotech — Recent Corporate Announcements

1. Headwinds and Challenges

  • Shareholder dissent on the enhanced Section 185 limits. At the 41st AGM held on July 31, 2026, the special resolution approving enhanced limits for advancing loans, providing guarantees and securities to subsidiary, associate and joint venture companies drew the weakest support of all six resolutions. Only 81.64% of votes polled were in favour, with 18.36% against. Public institutions were split, with 43.40% in favour and 56.60% against. This was the only resolution where promoter/promoter group were interested, and their votes were not polled on it (0 votes cast by promoters on this item), so the outcome rested on public shareholders.
  • Minority opposition on other items. Public institutions recorded 2.00% of votes against the adoption of annual audited standalone and consolidated financial statements, 1.93% against the re-appointment of Mr. Ankur Vaid as a director retiring by rotation, and 0.10% against the dividend declaration. These are small but visible pockets of institutional dissent.
  • Low physical attendance at the AGM. No shareholders were present in person or through proxy; participation was entirely through video conferencing (4 promoter/promoter group and 34 public shareholders) and remote e-voting.

2. Tailwinds and Growth Prospects

  • All resolutions passed with requisite majority. The six items transacted at the 41st AGM on July 31, 2026 were duly passed, covering adoption of the annual audited standalone and consolidated financial statements for FY ended March 31, 2026, declaration of dividend for FY2025-26, re-appointment of Mr. Ankur Vaid (DIN: 01857225) as a director retiring by rotation, appointment of Mrs. Ekta Gupta as an Independent Director, approval of enhanced Section 185 limits for loans/guarantees/securities to subsidiary, associate and joint venture companies, and ratification of cost auditors’ remuneration.
  • Enhanced financing flexibility. The approval of enhanced limits under Section 185 gives the company greater headroom to extend loans, guarantees and securities to subsidiary, associate and joint venture companies, which supports funding flexibility across its group structure.
  • Board strengthening. The appointment of Mrs. Ekta Gupta as an Independent Director was approved as a special resolution with 100% of votes polled in favour (excluding negligible votes against), which the company can draw on for governance and oversight.
  • Continued investor engagement. The company scheduled an investor conference with Phillip Capital PCG Group Meeting on August 26, 2026 in Ahmedabad, indicating ongoing engagement with institutional investors.
  • Q1 FY2026-27 results announced. The Board of Directors, at its meeting on July 31, 2026, considered and approved the unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, with a Limited Review Report issued by M/s. BSR & Co. LLP, the Statutory Auditors.
  • No defaults or adverse audit qualifications. The company disclosed no outstanding default on loans and debt securities, no deviation or variation in proceeds of public/rights/preferential/QIP issues, no related party transaction disclosure requirement for the quarter, and no audit qualifications requiring a statement of impact.

3. Key Risks

  • Governance and related-party sensitivity. The relatively high 18.36% votes against the Section 185 resolution, and the majority of public institutional votes cast against it (56.60%), indicate that a significant portion of institutional shareholders were not supportive of the enhanced limits for loans/guarantees/securities to group entities. This is a governance-sensitive area that could attract continued scrutiny.
  • Concentration of promoter holding. Promoter and promoter group held 46,116,608 shares, representing approximately 44.08% of the total 104,616,204 shares. On resolutions where promoters are interested (such as the Section 185 item), the outcome depends heavily on public shareholders, as demonstrated by the split institutional vote.
  • Dependence on public shareholder participation. With no physical attendance and voting entirely through remote e-voting and video conferencing, outcomes on contested items are determined by the level of public shareholder participation. On the Section 185 resolution, only 41.44% of outstanding shares were polled, versus over 85% on the other resolutions.

4. Management Guidance Versus Observed Business Performance

  • The supplied material does not contain forward-looking management guidance or financial projections against which observed performance can be compared.
  • The observable performance-related disclosures are: the Board approved the unaudited standalone and consolidated financial results for Q1 ended June 30, 2026 on July 31, 2026, accompanied by a Limited Review Report from the Statutory Auditors, M/s. BSR & Co. LLP; and the AGM adopted the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, together with the Board’s and Statutory Auditors’ reports.
  • A dividend on equity shares for the financial year ended March 31, 2026 was declared and passed with 99.98% of votes polled in favour.
  • No specific financial figures, growth rates, or guidance statements are provided in the source material, so no guidance-versus-performance comparison can be made.

Broker Timeline

1 broker calls · 2023-11-30 to 2023-11-30

   

Copyright © 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.

🐞